190 related articles for article (PubMed ID: 12778058)
1. Neoadjuvant docetaxel for operable breast cancer induces a high pathological response and breast-conservation rate.
Amat S; Bougnoux P; Penault-Llorca F; Fétissof F; Curé H; Kwiatkowski F; Achard JL; Body G; Dauplat J; Chollet P
Br J Cancer; 2003 May; 88(9):1339-45. PubMed ID: 12778058
[TBL] [Abstract][Full Text] [Related]
2. Weekly docetaxel as neoadjuvant chemotherapy for stage II and III breast cancer: efficacy and correlation with biological markers in a phase II, multicenter study.
Estévez LG; Cuevas JM; Antón A; Florián J; López-Vega JM; Velasco A; Lobo F; Herrero A; Fortes J
Clin Cancer Res; 2003 Feb; 9(2):686-92. PubMed ID: 12576436
[TBL] [Abstract][Full Text] [Related]
3. Docetaxel as neoadjuvant chemotherapy in patients with stage III breast cancer.
Gradishar WJ
Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):15-8. PubMed ID: 9364536
[TBL] [Abstract][Full Text] [Related]
4. A multicentre phase II study of docetaxel 75 mg m-2 as first-line chemotherapy for patients with advanced breast cancer: report of the Clinical Screening Group of the EORTC. European Organization for Research and Treatment of Cancer.
Dieras V; Chevallier B; Kerbrat P; Krakowski I; Roche H; Misset JL; Lentz MA; Azli N; Murawsky M; Riva A; Pouillart P; Fumoleau P
Br J Cancer; 1996 Aug; 74(4):650-6. PubMed ID: 8761385
[TBL] [Abstract][Full Text] [Related]
5. Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions.
Goble S; Bear HD
Surg Clin North Am; 2003 Aug; 83(4):943-71. PubMed ID: 12875604
[TBL] [Abstract][Full Text] [Related]
6. Taxanes for breast cancer: an evidence-based review of randomized phase II and phase III trials.
Sparano JA
Clin Breast Cancer; 2000 Apr; 1(1):32-40; discussion 41-2. PubMed ID: 11899388
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of docetaxel and epirubicin in Chinese patients with metastatic breast cancer.
Yeo W; Mok TS; Tse KK; Kwan WH; Lam KC; Ho WM; Chiu SK; Chan AT; Leung TW; Mo FK; Johnson PJ
Anticancer Drugs; 2002 Jul; 13(6):655-62. PubMed ID: 12172512
[TBL] [Abstract][Full Text] [Related]
8. Pathological and clinical response of a primary chemotherapy regimen combining vinorelbine, epirubicin, and paclitaxel as neoadjuvant treatment in patients with operable breast cancer.
Abrial C; Van Praagh I; Delva R; Leduc B; Fleury J; Gamelin E; Sillet-Bach I; Penault-Llorca F; Amat S; Chollet P
Oncologist; 2005 Apr; 10(4):242-9. PubMed ID: 15821244
[TBL] [Abstract][Full Text] [Related]
9. The role of docetaxel (Taxotere) in neoadjuvant chemotherapy of breast cancer.
Costa SD; von Minckwitz G; Raab G; Blohmer JU; Dresel V; Eidtmann H; Hilfrich J; Jackisch C; Merkle E; Gademann G; Kaufmann M
Semin Oncol; 1999 Jun; 26(3 Suppl 9):24-31. PubMed ID: 10426456
[TBL] [Abstract][Full Text] [Related]
10. Activity and toxicity of docetaxel (Taxotere) in women with previously treated metastatic breast cancer.
Shapiro JD; Millward MJ; Rischin D; Davison JD; Michael M; Francis PA; Ganju V; Toner GC
Aust N Z J Med; 1997 Feb; 27(1):40-4. PubMed ID: 9079252
[TBL] [Abstract][Full Text] [Related]
11. Docetaxel as neoadjuvant therapy for radically treatable stage III non-small-cell lung cancer: a multinational randomised phase III study.
Mattson KV; Abratt RP; ten Velde G; Krofta K
Ann Oncol; 2003 Jan; 14(1):116-22. PubMed ID: 12488303
[TBL] [Abstract][Full Text] [Related]
12. Docetaxel vs doxorubicin in metastatic breast cancer resistant to alkylating chemotherapy.
Chan S
Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):19-24. PubMed ID: 9364537
[TBL] [Abstract][Full Text] [Related]
13. A multicentre phase II study of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer: report of the Clinical Screening Group of the EORTC.
Fumoleau P; Chevallier B; Kerbrat P; Krakowski Y; Misset JL; Maugard-Louboutin C; Dieras V; Azli N; Bougon N; Riva A; Roche H
Ann Oncol; 1996 Feb; 7(2):165-71. PubMed ID: 8777173
[TBL] [Abstract][Full Text] [Related]
14. Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada-Clinical Trials Group.
Trudeau ME; Eisenhauer EA; Higgins BP; Letendre F; Lofters WS; Norris BD; Vandenberg TA; Delorme F; Muldal AM
J Clin Oncol; 1996 Feb; 14(2):422-8. PubMed ID: 8636752
[TBL] [Abstract][Full Text] [Related]
15. Sequential addition of an anthracycline-based regimen to docetaxel as neoadjuvant chemotherapy in patients with operable breast cancer.
Amat S; Mouret-Reynier MA; Penault-Llorca F; Leheurteur M; Delva R; Coudert B; Leduc B; Dauplat J; Curé H; Chollet P
Clin Breast Cancer; 2006 Aug; 7(3):262-9. PubMed ID: 16942644
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
Hurvitz SA; Martin M; Symmans WF; Jung KH; Huang CS; Thompson AM; Harbeck N; Valero V; Stroyakovskiy D; Wildiers H; Campone M; Boileau JF; Beckmann MW; Afenjar K; Fresco R; Helms HJ; Xu J; Lin YG; Sparano J; Slamon D
Lancet Oncol; 2018 Jan; 19(1):115-126. PubMed ID: 29175149
[TBL] [Abstract][Full Text] [Related]
17. Docetaxel administered on a weekly basis for metastatic breast cancer.
Burstein HJ; Manola J; Younger J; Parker LM; Bunnell CA; Scheib R; Matulonis UA; Garber JE; Clarke KD; Shulman LN; Winer EP
J Clin Oncol; 2000 Mar; 18(6):1212-9. PubMed ID: 10715290
[TBL] [Abstract][Full Text] [Related]
18. Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer.
Piccart MJ; Klijn J; Paridaens R; Nooij M; Mauriac L; Coleman R; Bontenbal M; Awada A; Selleslags J; Van Vreckem A; Van Glabbeke M
J Clin Oncol; 1997 Sep; 15(9):3149-55. PubMed ID: 9294478
[TBL] [Abstract][Full Text] [Related]
19. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer.
Chan S; Friedrichs K; Noel D; Pintér T; Van Belle S; Vorobiof D; Duarte R; Gil Gil M; Bodrogi I; Murray E; Yelle L; von Minckwitz G; Korec S; Simmonds P; Buzzi F; González Mancha R; Richardson G; Walpole E; Ronzoni M; Murawsky M; Alakl M; Riva A; Crown J;
J Clin Oncol; 1999 Aug; 17(8):2341-54. PubMed ID: 10561296
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of doxorubicin/docetaxel/cyclophosphamide for locally advanced and metastatic breast cancer: results from NSABP trial BP-58.
Smith RE; Anderson SJ; Brown A; Scholnik AP; Desai AM; Kardinal CG; Lembersky BC; Mamounas EP
Clin Breast Cancer; 2002 Dec; 3(5):333-40. PubMed ID: 12533263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
